Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2008

View Archived Issues

Ranbaxy patents novel muscarinic receptor antagonists

New analgesic agents imparted in recent patent literature

Novel treatments for dermatological disorders disclosed in recent patents

Sanofi pasteur's acquisition of Acambis completed

Manageable levels of neuropathy in breast cancer patients receiving eribulin

Novel GIP antagonist shows efficacy in preclinical models of obesity and type 2 diabetes

Positive phase I interim results of XOMA-052 in type 2 diabetes

Almirall receives payment from Forest as part of aclidinium collaboration

Arana Therapeutics provides update on recent pipeline activity

Safety results presented at the WSC from the V-10153 stroke thrombolysis trial

LAU-0901 neuroprotective in a rat model of focal cerebral ischemia

BioMS receives milestone payment based on positive review of MAESTRO-01 trial

MAP completes enrollment in phase III nebulized budesonide trial in children with asthma

ChemBridge enters into new discovery alliance with AstraZeneca

Discovery Laboratories completes response to FDA approvable letter for Surfaxin

BIO-11006 shows promise as a COPD treatment

Dyax completes BLA for DX-88 in hereditary angioedema

Inspire requests SPA process for Prolacria for dry eye

Independent Data Safety Monitoring supports continuation of Iluvien trial

Cellerant Therapeutics receives contract for acute radiation syndrome treatment

CHMP issues positive opinion for olanzapine long-acting injection in schizophrenia

Concert commences phase I CTP-347 trial in healthy volunteers

FDA approves Nasacort AQ Nasal Spray for children with allergic rhinitis

ImClone starts enrollment in phase II IMC-A12 trial in advanced breast cancer

RegeneRx enrolls first subject in phase Ib RGN-352 trial

Xenome evaluates XEN-2174 in phase II trial in acute pain

Thallion enrolls first patient in phase II TLN-4601 trial; FDA approves trial in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...